New scan could reveal hidden lung inflammation
NCT ID NCT03492762
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a radioactive tracer called Cu-DOTA-ECL1i that binds to certain inflammatory cells in the lungs. Researchers will use PET scans to see how the tracer spreads in people with fibrotic lung disease, comparing it to CT scans and clinical status. The goal is to develop a better way to track inflammation and guide treatment. The study enrolls 110 participants, including healthy never-smokers and current smokers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cu-DOTA-ECL1i (a radioactive imaging tracer)
- What this could lead to
- If successful, this imaging method could help doctors see inflammation in the lungs more clearly, leading to better diagnosis and personalized treatment for fibrotic lung diseases.
- What could go wrong
- This is a very early (Phase 1) study focused on imaging, not treatment. It may not lead to direct patient benefits, and the tracer's effectiveness in different lung conditions is still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE FIBROTIC LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.